Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675317 | 1.00 | ITGA4 (0.49) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL16447966 | 0.84 | ITGA4 (0.48) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL31407351 | 0.82 | TACR1 (0.60) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL3376451 | 0.82 | TACR1 (0.60) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL3376442 | 0.82 | TACR1 (0.60) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL8650372 | 0.82 | SCN9A (0.52) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL8650368 | 0.82 | SCN9A (0.52) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL24981983 | 0.81 | ACE (0.49) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL21639292 | 0.81 | ACE (0.49) | ITGA4ITGB7ACESCN9AITGB3 | |
| SCHEMBL3553357 | 0.81 | ACE (0.49) | ITGA4ITGB7ACESCN9AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173128-B2 | Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody | IRM LLC (BM) | 2012-05-08 | — | — | US | disclosed |
| US-8173128-B2 | Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody | IRM LLC (BM) | 2012-05-08 | — | — | US | disclosed |
| US-8173128-B2 | Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody | IRM LLC (BM) | 2012-05-08 | — | — | US | disclosed |
| EP-1576179-B1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2010-09-15 | — | — | EP | disclosed |
| US-7229617-B2 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-12 | — | — | US | disclosed |
| US-7229617-B2 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-12 | — | — | US | disclosed |
| US-20070128204-A1 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-07 | — | — | US | disclosed |
| US-20070128204-A1 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-07 | — | — | US | disclosed |
| US-20070128204-A1 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-07 | — | — | US | disclosed |
| EP-1576179-A4 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2007-06-06 | — | — | EP | disclosed |
| EP-1399468-B1 | 2-((N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL)-AMINO)-ALKYLBORONIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2006-02-15 | — | — | EP | disclosed |
| US-20050239716-A1 | 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives | FURET PASCAL | 2005-10-27 | — | — | US | disclosed |
| EP-1576179-A2 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2005-09-21 | — | — | EP | disclosed |
| US-6933290-B2 | 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | NOVARTIS AG (CH) | 2005-08-23 | — | — | US | disclosed |
| US-20050079172-A1 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-04-14 | — | — | US | disclosed |
| US-20040167337-A1 | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | NOVARTIS AG (CH) | 2004-08-26 | — | — | US | disclosed |
| WO-2004050895-A2 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2004-06-17 | — | — | WO | disclosed |
| EP-1399468-A1 | 2-((N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL)-AMINO)-ALKYLBORONIC ACID DERIVATIVES | Novartis AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002096933-A1 | 2-{[N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL]-AMINO}-ALKYLBORONIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167337-A1 | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | AADAT, BCAT1, BCAT2 | ITGA4 1921/4885ITGB7 386/4885ACE 932/4885 |
| US-20050239716-A1 | 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives | AADAT, PIGS, SLC1A5 | ITGA4 811/4885ITGB7 137/4885ACE 261/4885 |
| US-20050079172-A1 | Methods and compositions for inducing apoptosis in cancer cells | BAD, BAX, CASP3 | ITGA4 217/4885ITGB7 582/4885ACE 4734/4885 |
| US-20070128204-A1 | Methods and compositions for inducing apoptosis in cancer cells | BAD, BAX, BID | ITGA4 1654/4885ITGB7 643/4885ACE 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.